Drug Survival of Risankizumab Vs Other Biologics After 25 Months of Treatment Among Patients With Psoriatic Arthritis: An Interim Analysis of the VALUE Study. J of Skin 2025, 9 (6), s695. https://doi.org/10.25251/m10xva58.